Previous research has identified an association between low vitamin D status and the risk and severity of acute respiratory infections1,2, leading to suggestion that correction of vitamin D deficiency may improve outcome in COVID-19 patients. This study aimed to elucidate the association between low vitamin D status and adverse clinical outcomes including mortality amongst Covid-19 inpatients.
Two-hundred participants were recruited from St. James Hospital, Dublin. Indices of disease severity included duration of hospitalisation, number of signs and symptoms experienced, requirement for oxygen support and ICU admission and mortality. Pearson's and Spearman's correlation tests were used to evaluate the association between serum vitamin D (25(OH)D), interleukin-6 (IL-6), D-dimer, fibrinogen and CD25 levels and disease outcome.
Overall, 138 patients (69%) had measured 25(OH)D levels; 23% (n = 32) were classified as ‘deficient’ (25(OH)D < 30 nmol/L), 25% (n = 34) were classified as ‘insufficient’ (25(OH)D of 30–49.9 nmol/L) and 52% (n = 72) were classified as ‘sufficient’ (25(OH)D ≥ 50 nmol/l). No significant correlation was observed between circulating 25(OH)D and age. However, serum 25(OH)D was inversely associated with IL-6 (Β = −0.696, p = 0.036) and D-dimer (Β = −13.71, p = 0.002). High IL-6 levels were associated with an increased likelihood of infiltrates on chest X-ray (OR = 3.615, p = 0.044), while high D-Dimer levels were associated with an increased risk of admission to ICU (OR = 15.304, p = 0.012), and an increased likelihood of requiring oxygen support (OR = 4.035, p = 0.004). Clinically, vitamin D deficiency was associated with an increased risk of infiltrates on chest X-ray (OR = 2.253, p = 0.026). There was also a tendency towards lower vitamin D levels in patients who died (n = 15) than in those who survived (n = 123) (21.8 nmol/L vs. 37.8 nmol/L, p = 0.054).
These data suggest that low vitamin D status may be associated with poorer clinical and biometric profiles and increased mortality in hospitalised Covid-19 patients. The association of low vitamin D status with higher IL-6 and higher D-dimer levels, and the association of these biometric markers with more severe clinical outcomes in this and other studies(Reference Jain and Chaurasia3,Reference Baktash and Hosack4) , suggest that these pro-inflammatory and pro-thrombotic mediators may lie at an intermediate point in the causal pathway between low vitamin D status and poorer clinical outcomes including mortality in hospitalised Covid-19 patients.
